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Abstract: Continuous glucose monitoring (CGM) devices, with their 1-5 minute measurement 
interval, allow blood glucose dynamics to be captured more frequently and less invasively than 
traditional measures of blood glucose concentration (BG). These devices are primarily designed for 
the use in type 1 and type 2 diabetic patients to aid BG regulation. However, because of their 
increased measurement frequency and reduced invasiveness CGM devices have been recently 
applied to other subject cohorts, such as intensive care patients and neonates. One unexamined 
cohort is athletes. Continuous monitoring of an athlete’s BG has the potential to increase race 
performance, speed recovery, and aid training, as BG can reflect metabolic and inflammatory 
conditions. However, before these benefits can be realized the accuracy and performance of CGM 
devices in active athletes must be evaluated. 
 
Two Ipro2 and one Guardian Real-time CGM devices (Medtronic Minimed, Northridge, CA, USA) 
were inserted into 10 subjects (resting HR < 60 beats per minute (bpm), training 6-15hrs per week). 
For each participant a fasting continuous exercise test was carried out until failure, ~90mins, and 
glucoses boluses were given at 30mins (0.5g/kg) and failure (1g/kg). Reference BG measurements 
were taken every 10min for the first 60min, every 5min until failure + 30min and every 10min until 
failure + 60min with an Abbott Optimum Xceed glucometer.  Pre-glucose bolus, all sensors perform 
better compared to results seen in diabetic cohorts with median mean absolute relative difference 
(MARD) of 9.7%, 9.6% and 11.1% for the two Ipro2’s and the Real-time, respectively. However, there 
is increased error post-bolus likely due to the gradient of BG change being higher, so the delay in 
transport to interstitial fluid and sensor results in a larger discrepancy from reference values. CGM 
devices agree very well with each other during rigorous exercise with median cross-correlation 
coefficients between 0.88 and 0.97 for the different sensor pairings. This good correlation between 
all three signals suggests the error between glucose measured by CGM and from blood is not 
random, but likely due to transport/uptake effects. As the interstitial fluid is the medium from which 
glucose enters muscle cells, this CGM value might be more useful than BG in determining glucose 





Continuous glucose monitoring (CGM) devices, with their 1-5 minute measurement interval, allow 
blood glucose concentration (BG) dynamics to be captured more frequently and less invasively than 
traditional measures of BG. CGM devices typically consist of a small pager-like monitoring device that 
receives a signal from a sensor inserted into the subcutaneous layer. The sensor creates a signal using 
the glucose oxidase reaction and produces a current proportional to the glucose concentration in the 
surrounding interstitial fluid. Calibration algorithms convert the signal into a BG value by comparing it 
to calibration BG measurements, which are entered into the monitor by the user every ~6-8hrs. 
These devices are primarily designed for the use in type 1 and type 2 diabetic individuals to aid BG 
regulation and are well studied in this cohort [1, 2]. However, because of the increased measurement 
frequency and reduced invasiveness they have recently been applied to other cohorts, such as 
intensive care patients and neonates with varying success [3-10].  Another cohort where CGM may be 
beneficial is athletes. This cohort is yet to be thoroughly investigated but optimisation of an athlete’s 
BG has the potential to increase race performance, speed recovery, and aid training [11-15].  
 In particular,  there is ongoing research to improve carbohydrate delivery and oxidation, resulting in 
less accumulation of carbohydrate in the gastrointestinal track to decrease gastrointestinal problems 
during prolonged exercise [11]. CGM data could aid optimal carbohydrate delivery by allowing an 
athlete to know the best time and the amount of carbohydrate to consume. However, before these 
benefits can be realised, the accuracy and performance of CGM devices in active, trained athletes 
must be evaluated, which has not been done before and is a very different cohort to those with 
metabolic dysfunction. Hence, the aim of this paper is to characterise the accuracy and performance 






2. SUBJECTS & METHODS 
2.1 Subjects and Experiments  
Ten fit, healthy subjects were recruited under informed written consent for this study. Table 1 
summarizes the cohort demographics. Seven out of the ten participants cycled regularly and all 
subjects trained >6 hours per week in a range of endurance based sports, predominantly running and 
cycling. The research procedures and use of data were approved by the University of Canterbury Ethics 
Committee. 
Table 1. Cohort demographics of the participants. Data are presented as median [interquartile range] 
where appropriate 
Number 10 
Age (yr) 28 [23 37] 
Gender (M/F) 7/3 
BMI (kg/m2) 22 [21 24] 
Resting HR (bpm)  55 [53 56] 
VO2max (mL/kg/min) 46 [39 59] 
Trained Cyclist (Y/N)  7/3 
Length of CGM data (hr) 140 [105 141] 
 
Two Ipro2 and one Guardian Real-time CGM devices (Medtronic Minimed, Northridge, CA, USA) were 
inserted into the abdomen of each athlete ~24 hours prior to the first ‘fasted exercise test’. The CGM 
device remained in each subject for 4 - 6 days.  For all athletes, the Ipro CGM devices were both 
inserted in to the left side of the abdomen and the Guardian in the right side. These devices are 
referred to as sensor 1 (SG1), the lower left abdomen sensor, sensor 2 (SG2), the upper left abdomen 





Figure 1: Photo showing the locations of each CGM devices 
 
During the 6 days of CGM:  
• Blood glucose was measured 4 times per day prior to meals and sleeping. These 
measurements were used to calibrate the device (calibration BG)   
• All meals and snacks were recorded and carbohydrate intake calculated 
• Any additional exercise was also recorded and energy expenditure estimated  
 
 







Fasting exercise tests were carried out as shown in Figure 2. Subjects were required not to exercise 
the day before the test. On the day of testing, the exercise protocol typically began at 8am and is 
defined: 
• 0-60min: Cycling on a stationary trainer (Cyclus 2, RBM elektronik-automation GmbH, Lepzig, 
Germany) after overnight fasting in the submaximal endurance HR zone <70%VO2max 
resulting in a resistance set to 2W/kg for female and untrained cyclists or 2.5W/kg.  
• 30min: Consume a 0.5g/kg of body weight (30-45g) glucose drink 
• 60 – exhaustion (~90min): Steadily increase effort until exhaustion by increasing required 
power by 20W every 5 minutes.  
• Exhaustion: Consume a 1g/kg of body weight (60-90g) glucose drink  
Reference BG measurements: 
• 0-60min: Every 10min 
• 60 – exhaustion+ 30min (~120min): Every 5min  
• Exhaustion+30min (~120min) - exhaustion+60min (~150min) : Every 10min 
Reference measurements were not used for calibration.   
Other measurements:  
- Body weight, BMI, Body composition Analyser (InBody230, InBody Bldg, Seoul, Korea) 
- Indirect calorimetry (MetaLyzer 3B - R2, CORTEX Biophysik GmbH, Lepzig, Germany) 
Reference and calibration BG measurements were taken using capillary finger stick measurements 
and the Abbott Optimum Xceed (Abbott Diabetes Care, Alameda, CA) glucometer. The Abbott device 





2.2 Analysis  
To assess the accuracy of the CGM during exercise the mean absolute relative difference (MARD) was 
calculated between reference BG measurements collected during the fasting tests and the CGM trace:  
𝑀𝐴𝑅𝐷 = 𝑚𝑒𝑎𝑛(𝑎𝑏𝑠 (
𝐶𝐺𝑀−𝐵𝐺
𝐵𝐺
)) ∗ 100         (Eq. 1) 
MARDs were assessed during three different phases during the trial, 0-30min, 30min-exhuastion and 
exhaustion – exhaustion+60min. MARD was also calculated over the entire test.  This consideration of 
different phases allowed an assessment of accuracy when glucose levels were rapidly changing, after 
the each glucose bolus, and when they are relatively stable, during exercise.   
To assess the agreement of the CGM devices during the exercise test, zero-lag cross-correlation was 
applied. Zero-lag cross-correction is the dot product applied to as shown in Equation 2 to two equal 
length signals with no time shift, and yields a measure to measure agreement.  
cos 𝜃  = (
𝐴.𝐵
||𝐴||||𝐵||
)        Eq 2. 
 
Where A = [a1, a2 …. an] represents the n x 1 vector of measurements from one CGM signal and B = [b1, 
b2 …. bn] the n x 1 vector of measurements from the other. The resultant angle,𝜃, shows the trend 
similarity between two vectors and its cosine has values from -1 and +1 demonstrating opposing to 
complete agreement. Thus, it uses the inner product definition to define how much of vector A is 
projected on to vector B, where 1 indicates equal vectors. This resulted value is referred to as the zero 
lag correlation co-efficient. All signals were first mean-centred to remove bias.  
 
3. RESULTS & DISCUSSION 
Figure 3 provides an example of the good sensor agreement seen over the 6 days of monitoring. Both 
sensor current and sensor glucose visually agree well across the entire 6 days of monitoring. The 
  
 
results in Figure 4, Table 2 and Table 3 clearly show Ipro2 CGM devices, SG1 and SG2, are accurate 
during intense exercise. The MARD values in Table 2 and Table 3 are equivalent if not better than the 
performance reported for CGM in diabetic subjects [15, 19-22] .  
Bailey et al. [15] reported an overall MARD of 13.6% from a study using the same sensors in 90 type 1 
diabetic subjects. Overall, the Ipro2 devices match this performance and perform better than 
expected during 0 – 30min of steady state exercise with median MARD of 9.7% and 9.6% for SG1 and 
SG2, respectively. Even during times of rapid glucose change after the glucose boluses were given and 
changes in exercise intensity (Figure 4) the Ipro2 CGM devices prove accurate resulting in an overall 
median [IQR] MARD of 11.2 [10.8 13.2]% and 13.6 [11.9 14.7]%. 
However, the Guardian real-time performance is mixed. The literature reports an overall MARD of 15-
17.8% for Guardian CGM in diabetic individuals [20-22]. During the first 30min of exercise the Guardian 
out-performs the expected result with a median [IQR] MARD of 11.1 [7.2 16.0] %. However, across the 
entire test the Guardian devices only achieved a median [IQR] MARD of 20.3 [16.1 23.8] %. This result 
indicates the Guardian struggles to track the fast changing glucose dynamics once the glucose boluses 
are taken and exercise intensity changes.  
The Guardian device is calibrated in real-time and provides a real time approximation of blood glucose 
levels on a monitor that communicates wirelessly with the sensor.  This real-time approximation 
means that the device can only use the previous and current calibration measurements to calibrate 
the current signal from the interstitial fluid. In comparison, the Ipro2 devices (SG1 ad SG2) store all 
current data on the sensor which is then downloaded at the end of monitoring and calibrated 
retrospectively. Thus, both future and past measurements can be used for calibrating the iPro2 signal. 
However, to generate a real-time control algorithm for athlete nutrition a real time device like the 
guardian would be necessary.  However these issues could be offset if glucose ingestion, such as from 





Figure 3: Examples of current and sensor glucose data captured over the 6 days of monitoring. Subject 
ATH03 is presented in A and ATH06 in B.  
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Figure 4: Blood glucose reference values. CGM values and glucose bolus data for each athlete. Ath01-
Ath10 in descending order as reading from right to left. 


































































































































































































































































BG Ref SG1 SG2 SG realtime Glucose Bolus
  
 
Table 2: MARD results for each athlete and sensor combination for the entire duration of the test. The 
gaps in column three represent where sensor failures prevented the collection of CGM data. 
Subject SG1 MARD (%) SG2 MARD (%) SGrealtime MARD (%) 
ATH01 11.2 13.4 19.0 
ATH02  15.2 14.9 15.9 
ATH03 9.0 8.9 24.9 
ATH04 12.3  16.3 
ATH05 13.8 11.9 10.7 
ATH06 12.7 13.8 23.9 
ATH07 11.1 32.3 23.8 
ATH08 10.6 14.2 20.5 
ATH09 10.9 11.9 20.3 
ATH10 20.0  28.9 
Median[IQR] 11.2 [10.8 13.2] 13.6 [11.9 14.7] 20.3 [16.1 23.8] 
 
Table 3: MARD presented as median [IQR] of the cohort for each stage during the exercise test. 
 0 – 30min 30min – Exhaust  Exhaust – Exhaust+60min 
SG1 9.7 [6.0 17.8] 11.3 [8.9 13.8] 11.4 [8.5 15.7] 
SG2 9.6 [7.3 17.5] 12.5 [10.1 17.4] 17.0 [12.1 20.3] 
SGrealtime 11.1 [7.2 16.0] 19.9 [16.9 23.5] 21.1 [18.2 27.0] 
 
More accurate results during steady state exercise compared to published results in diabetes cohorts 
are likely due to interstitial fluid not being actively pumped like blood. Interstitial fluid relies on muscle 
movement to circulate and mix. Thus, it can be expected that during exercise more accurate results 
are seen as the rigorous movement and increased overall blood flow allows rapid mixing and 
equilibrium between the blood and interstitial fluid, as well as more accurate reference BG 
measurements due to high skin temperatures and increased circulation, where  Haupt et al. [23] and  




However, as evident with the real-time calibrated device, rapid mixing between the intestinal and 
blood is not enough to ensure ideal performance when large disturbances, such as glucose boluses, 
are added to the system. This increased error is likely due to the gradient of BG change being higher, 
so the delay in transport to interstitial fluid and sensor results in a larger discrepancy in measured 
values compared to a blood-based reference. 
The zero-lag correlation between all three sensors is very good, as seen in Table 4. SG1 and SG2 have 
a median [IQR] correlation coefficient of 0.97 [0.94 0.99]. It is expected that these signals would 
correlate the best as they are the same device inserted in the same side of the abdomen. Both SG1 
and SG2 also correlate very well with the SGrealtime, with median correlation coefficients of 0.90 and 
0.88 respectively. This good correlation between all three signals suggests that the error seen between 
glucose concentrations measured by CGM and from blood is not random, but likely due to effects such 
as transport delays and local glucose uptake. As the interstitial fluid is the medium from which glucose 
enters muscle cells, this CGM value might be more useful than BG in determining glucose availability 
for athletes.  
Table 4: Correlation coefficient for each sensor combination using the CGM data generated during the 
exercise test.  
Correlation Coefficient  SG1 vs. SG2 SG1 vs. SGrealtime SG2 vs. SGrealtime 
ATH01 0.99 0.90 0.89 
ATH02  0.98 0.97 0.98 
ATH03 0.96 0.92 0.81 
ATH04  0.80  
ATH05 0.98 0.89 0.95 
ATH06 1.00 0.81 0.79 
ATH07 0.92 0.96 0.84 
ATH08 0.74 0.32 0.87 
ATH09 0.95 0.81 0.89 
ATH10  0.96  
Median[IQR] 0.97 [0.94 0.99] 0.90 [0.81 0.95] 0.88 [0.83 0.91] 
  
 
3.1 Limitations  
This study is a proof of concept demonstration and thus the relatively small data set is a limitation. 
These tests were trialled in 10 athletes and results are likely to vary between individuals. However, 
there is a clear difference in signal quality between retrospective and real time devices, as well as 
between steady state exercise and periods of glucose disturbance. These differences also provide 
insight into how these devices might be more optimally used in the target, more sedentary cohort. 
Finally, the results justify investment in further research in to CGM and its use to optimise metabolism 
in athletic subjects. 
 
4. CONCLUSIONS 
Optimisation of an athlete’s BG via intra-event nutrition has the potential to increase race 
performance, speed recovery and aid training. During steady state exercise, all sensors perform better 
than results reported for diabetes cohorts, with median MARD of 9.7%, 9.6% and 11.1% for SG1, SG2 
and SGrealtime, respectively. However, there is increased error after a glucose bolus likely due to the 
gradient of BG change being higher, so the delay in transport to interstitial fluid and sensor results in 
a larger discrepancy to measured blood based reference values. CGM devices agree very well with 
each other during rigorous exercise with median zero-lag cross-correlation coefficients between 0.88 
and 0.97 for the different sensor pairings. This good correlation between all three signals suggests the 
error between glucose measured by CGM and from blood is not random, but likely due to 
transport/uptake effects differing the blood and CGM values. As the interstitial fluid is the medium 
from which glucose enters muscle cells, this CGM value might be more useful than BG in determining 
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